Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbasi, Ahmed, Peeke, Stephen, Shah, Nishi, Mustafa, Jennat, Khatun, Fariha, Lombardo, Amanda, Abreu, Michelly, Elkind, Richard, Fehn, Karen, de Castro, Alyssa, Wang, Yanhua, Derman, Olga, Nelson, Randin, Uehlinger, Joan, Gritsman, Kira, Sica, R. Alejandro, Kornblum, Noah, Mantzaris, Ioannis, Shastri, Aditi, Janakiram, Murali, Goldfinger, Mendel, Verma, Amit, Braunschweig, Ira, Bachier-Rodriguez, Lizamarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942268/
https://www.ncbi.nlm.nih.gov/pubmed/31900191
http://dx.doi.org/10.1186/s13045-019-0838-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942268/
https://www.ncbi.nlm.nih.gov/pubmed/31900191
http://dx.doi.org/10.1186/s13045-019-0838-y

Ejemplares similares